3.8 Article

Needle device-assisted single-incision laparoscopic gastrectomy for early gastric cancer: A propensity score-matched analysis

Journal

ASIAN JOURNAL OF ENDOSCOPIC SURGERY
Volume 14, Issue 3, Pages 511-519

Publisher

WILEY
DOI: 10.1111/ases.12909

Keywords

gastrectomy; laparoscopy; needlescopic surgery

Categories

Ask authors/readers for more resources

The needle device-assisted single-incision laparoscopic gastrectomy (NA-SILG) is a safe and feasible technique for treating early gastric cancer in slim figure patients. It shows comparable short and long-term outcomes to conventional laparoscopic gastrectomy (CLG) but is less invasive and results in less postoperative pain.
Introduction: Single-incision laparoscopic gastrectomy can be difficult because of complex instrumentation and a limited working angle. We standardized a needle device-assisted single-incision laparoscopic gastrectomy (NA-SILG) procedure for early gastric cancer in 2013. Herein, we present our technique and evaluate it in comparison to the conventional laparoscopic gastrectomy CLG) technique. Methods: We retrospectively reviewed medical records of 149 patients who underwent a NA-SILG or distal (CLG) for early gastric cancer between January 2013 and August 2016. We performed 1:1 propensity score matching between the two groups. Results: Eighteen patients who underwent a NA-SILG and 131 who underwent a CLG were included. Almost all patients were in clinical stage IA. Operative times were 216 +/- 29.7 minutes and 220 +/- 51.7 minutes for the NA-SILG and CLG groups, respectively; the median intraoperative bleeding amounts were 5 mL and 10 mL for the NA-SILG and CLG groups, respectively. The median number of retrieved lymph nodes was 41.5 and 57 for the NA-SILG and CLG groups, respectively. The number of patients needing analgesics was significantly lower in the NA-SILG group (P = .003) than in the CLG group. Neither group had postoperative complications more severe than Clavien-Dindo classification III. Conclusion: Needle device-assisted SILG is safe and feasible for early gastric cancer treatment in slim figure patients. It has short and long-term outcomes comparable to the CLG but is less invasive and results in less postoperative pain.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available